Search by Drug Name or NDC
NDC 14537-0408-50 Isoplate .03; .037; .00082; .37; .53; .5; .008 g/100mL; g/100mL; g/100mL; g/100mL; g/100mL; g/100mL; g/100mL Details
Isoplate .03; .037; .00082; .37; .53; .5; .008 g/100mL; g/100mL; g/100mL; g/100mL; g/100mL; g/100mL; g/100mL
Isoplate is a INTRAVENOUS SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Terumo BCT Ltd.. The primary component is MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORM.
Product Information
| NDC | 14537-0408 |
|---|---|
| Product ID | 14537-408_18d184d6-1606-4e5c-a25f-6a4acf283358 |
| Associated GPIs | |
| GCN Sequence Number | n/a |
| GCN Sequence Number Description | n/a |
| HIC3 | n/a |
| HIC3 Description | n/a |
| GCN | n/a |
| HICL Sequence Number | n/a |
| HICL Sequence Number Description | n/a |
| Brand/Generic | n/a |
| Proprietary Name | Isoplate |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | SODIUM CHLORIDE, SODIUM GLUCONATE, SODIUM ACETATE, POTASSIUM CHLORIDE, MAGNESIUM CHLORIDE, SODIUM PHOSPHATE, DIBASIC, and POTASSIUM PHOSPHATE, MONOBASIC |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | SOLUTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | .03; .037; .00082; .37; .53; .5; .008 |
| Active Ingredient Units | g/100mL; g/100mL; g/100mL; g/100mL; g/100mL; g/100mL; g/100mL |
| Substance Name | MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORM |
| Labeler Name | Terumo BCT Ltd. |
| Pharmaceutical Class | Calculi Dissolution Agent [EPC], Increased Large Intestinal Motility [PE], Increased Large Intestinal Motility [PE], Increased Large Intestinal Motility [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Large Intestine Fluid/E |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | BN090067 |
| Listing Certified Through | 2024-12-31 |
Package
Package Images
NDC 14537-0408-50 (14537040850)
| NDC Package Code | 14537-408-50 |
|---|---|
| Billing NDC | 14537040850 |
| Package | 18 CONTAINER in 1 CASE (14537-408-50) / 500 mL in 1 CONTAINER |
| Marketing Start Date | 2013-03-05 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |
Standard Product Labeling (SPL)/Prescribing Information SPL 37932532-4fbf-4485-abe6-d2c9f9fc3b80 Details
HIGHLIGHTS OF PRESCRIBING INFORMATION
ISOPLATE SOLUTION
Platelet Additive Solution [PAS-F]
Sterile Fluid
Polyolefin Bag
Initial U.S. Approval: 2013
RECENT MAJOR CHANGES
| Dosage and Administration (2.2) | 5/2015 |
INDICATIONS AND USAGE
ISOPLATE SOLUTION - Platelet Additive Solution [PAS-F] is an isotonic solution to replace a portion of the plasma to store Platelets Pheresis Platelet Additive Solution (PAS) Added Leukocytes Reduced products collected using a hyperconcentrated collection on Terumo BCT's Trima Accel system. Platelets Pheresis PAS Added Leukocytes Reduced products are stored in a mix of 65% Isoplate and 35% plasma.
Platelets in ISOPLATE SOLUTION can be stored at a concentration range of 0.7 to 2.1 × 106/µL for up to 5 days at 20-24 °C with continuous agitation in the Terumo BCT ELP bag [citrated polyvinyl chloride (PVC)]. (1)
DOSAGE AND ADMINISTRATION
- ISOPLATE SOLUTION is added to hyperconcentrated platelets after the apheresis procedure is complete. (2)
- ISOPLATE SOLUTION may only be used with the Trima Accel system. For instructions on the use of the solution with the Trima Accel system, see the Trima Accel system operator's manual. (2.1)
- Follow the directions for connecting the ISOPLATE SOLUTION bag to the Trima Accel System. (2.2)
DOSAGE FORMS AND STRENGTHS
- 500 mL sterile fluid in polyolefin bag (3)
CONTRAINDICATIONS
- DO NOT INFUSE ISOPLATE SOLUTION DIRECTLY TO THE PATIENTS. (4)
WARNINGS AND PRECAUTIONS
- Verify that the ISOPLATE SOLUTION has been securely attached to the platelet additive solution line on the Trima Accel system tubing set using aseptic technique. (5)
ADVERSE REACTIONS
ISOPLATE SOLUTION is expected to cause adverse events that are seen with platelet transfusion. (6)
To report SUSPECTED ADVERSE REACTIONS, contact Terumo BCT, Inc. at 1-877-339-4228 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
USE IN SPECIFIC POPULATIONS
Revised: 5/2015
Table Of Contents
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
2.1 General Dosing Information
2.2 Administration
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
8 SPECIAL POPULATIONS
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
14 CLINICAL STUDIES
15 REFERENCES
16 HOW SUPPLIED/STORAGE AND HANDLING
- *
- Sections or subsections omitted from the full prescribing information are not listed.
1 INDICATIONS AND USAGE
ISOPLATE SOLUTION - Platelet Additive Solution [PAS-F] is an isotonic solution to replace a portion of the plasma to store Platelets Pheresis Platelet Additive Solution (PAS) Added Leukocytes Reduced products collected using a hyperconcentrated collection on Terumo BCT's Trima Accel system [See Dosage and Administration (2).]
Platelets Pheresis PAS Added Leukocytes Reduced products are stored in a mix of 65% ISOPLATE SOLUTION and 35% plasma. Platelets in the solution can be stored at a concentration range of 0.7 to 2.1 × 106/µL for up to 5 days at 20-24 °C with continuous agitation in the Terumo BCT ELP bag [citrated polyvinyl chloride (PVC)] [See Clinical Studies (14).]
2 DOSAGE AND ADMINISTRATION
2.1 General Dosing Information
ISOPLATE SOLUTION is added to hyperconcentrated platelets after the apheresis procedure is complete. It is not intended for direct intravenous infusion.
ISOPLATE SOLUTION may only be used with the Trima Accel system for automated blood collection. For instructions on the use of the solution with the Trima Accel system, see the Trima Accel system operator's manual.
2.2 Administration
- Ensure solution is the ISOPLATE SOLUTION and is within the expiration date.
- Inspect the bag. Do not use if the container is damaged, leaking or if there is any visible sign of deterioration.
- Use only if solution is clear and free of particulate matter.
- Protect from sharp objects.
Directions for Connecting the ISOPLATE SOLUTION Bag to the Trima Accel System
At the prompt to connect the platelet additive solution to the Trima Accel system tubing set:
- Remove the overwrap by pulling down at notch, and remove the ISOPLATE SOLUTION bag.
- Before use, perform the following checks [See Warnings and Precautions (5).]:
- Check for leaks by squeezing the bag. If leaks are found, discard bag.
- Ensure the solution is the ISOPLATE SOLUTION and is within the expiration date.
- Inspect the solution in good light. Bags showing cloudiness, haze, or particulate matter should not be used.
- Remove the protective cap from the port on the bag.
- Connect the bag to the Trima Accel system tubing set using aseptic technique and hang the solution.
- Break the frangible connector. When you break frangible connectors, bend them in both directions to ensure that you break them completely. Failure to do so may result in restricted flow.
- Proceed per the Trima Accel system operator's manual.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
3 DOSAGE FORMS AND STRENGTHS
500 mL ISOPLATE SOLUTION - Platelet Additive Solution [PAS-F] is a sterile isotonic solution in a polyolefin bag. Each 100 mL contains: Sodium Chloride 0.53 g; Sodium Gluconate 0.5 g; Sodium Acetate Trihydrate 0.37 g; Potassium Chloride 0.037 g; Magnesium Chloride Hexahydrate 0.03 g; Dibasic Sodium Phosphate Dihydrate 0.008 g; Monobasic Potassium Phosphate 0.00082 g; in Water for Injection.
5 WARNINGS AND PRECAUTIONS
6 ADVERSE REACTIONS
ISOPLATE SOLUTION is added to platelets after the apheresis procedure is complete. It is not for direct intravenous infusion. It is expected to cause adverse events that are normally associated with platelet transfusion.
6.1 Clinical Trials Experience
No adverse reactions were reported in the subjects infused with < 10 mL of radiolabeled platelets stored for 5 days in 65% ISOPLATE SOLUTION, and rinsed prior to infusion [See Clinical Studies (14).]
8 SPECIAL POPULATIONS
11 DESCRIPTION
ISOPLATE SOLUTION - Platelet Additive Solution [PAS-F] is an isotonic solution designed to replace a proportion of the plasma used in the storage of Platelet Pheresis, Leukocytes Reduced PAS products collected using a hyperconcentrated collection on Terumo BCT's Trima Accel system.
The solution is sterile, nonpyrogenic and contains no bacteriostatic or antimicrobial agents.
The formulas of the active ingredients are provided in Table 1.
| Ingredients | Molecular Formula | Molecular Weight |
|---|---|---|
| Sodium Chloride USP | NaCl | 58.44 |
| Sodium Acetate Trihydrate USP | CH3COONa∙3H2O | 136.08 |
| Potassium Chloride USP | KCl | 74.55 |
| Magnesium Chloride Hexahydrate USP | MgCl2∙6H2O | 203.30 |
| Dibasic Sodium Phosphate Dihydrate USP | Na2HPO4∙2H2O | 177.98 |
| Monobasic Potassium Phosphate NF | KH2PO4 | 136.09 |
| Sodium Gluconate USP | C6H11NaO7 | 218.14 |
Each 100 mL of ISOPLATE SOLUTION contains: Sodium Chloride USP 0.53 g; Sodium Gluconate USP 0.5 g; Sodium Acetate Trihydrate USP 0.37 g; Potassium Chloride USP 0.037 g; Magnesium Chloride Hexahydrate USP 0.03 g; Dibasic Sodium Phosphate Dihydrate USP 0.008 g; Monobasic Potassium Phosphate NF 0.00082 g; in Water for Injection USP.
pH may be adjusted with glacial Acetic Acid USP or Sodium Hydroxide NF pH: 7.4 (7.0-7.8).
Concentration of Electrolytes (mEq/liter): Sodium 141; Potassium 5; Magnesium 3; Chloride 98; Phosphate (HPO=4 ) 1 (0.5 mmole P/liter); Acetate (CH3COO–) 27; Gluconate (HOCH2(CHOH)4COO–) 23.
The polyolefin bag is not made with natural rubber latex or PVC. Di(2-ethylhexyl)phthalate (DEHP) is present only in sterile dock tube.
The bag is made from a multilayered film. It contains materials that have been tested to demonstrate the suitability of the container for storing pharmaceutical solutions. The solution contact layer is an elasticized polyolefin. The bag is nontoxic and biologically inert. The bag-solution unit is a closed system and is not dependent upon entry of external air during administration. The bag is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
ISOPLATE SOLUTION contains the following key components to maintain platelet function:
- Sodium chloride for osmolarity
- Acetate to fuel platelet metabolism
- Gluconate or phosphate for buffering
- Magnesium and potassium to reduce platelet activation1,2
This solution has no pharmacological effect; the solution provides the appropriate components for platelet function while allowing for a lower volume of plasma in the platelet product during storage.
14 CLINICAL STUDIES
In Vivo radiolabeled recovery and survival
A paired study was completed to verify that in vivo radiolabeled recovery and survival of hyperconcentrated leukocyte reduced platelets collected by apheresis on the Trima Accel system, diluted in ISOPLATE SOLUTION, and stored for five days (Test) meet FDA acceptance criteria in comparison with fresh autologous platelets (Control). Table 2 summarizes the in vivo radiolabeled platelet recovery and survival data.
| Recovery | Survival | |||||
|---|---|---|---|---|---|---|
| Test | Control | Test/Control | Test | Control | Test/Control | |
| % | % | % | Days | Days | % | |
| Average | 51.1 | 60.2 | 85 | 6.6 | 8.7 | 76 |
| St. Dev. | 10.9 | 10.2 | 10 | 1.2 | 0.9 | 12 |
| Min | 32.6 | 40.4 | 66 | 4.5 | 6.4 | 52 |
| Max | 84.1 | 82.8 | 102 | 8.8 | 10.0 | 104 |
The primary outcomes for this study were:
Recovery: Test minus 66% Control is equal to or greater than zero with one-sided 97.5% confidence limit
Survival: Test minus 58% Control is equal to or greater than zero with one-sided 97.5% confidence limit
Both primary outcomes were met for hyperconcentrated leukocyte reduced platelets collected on the Trima Accel system and stored in ISOPLATE SOLUTION.
In Vitro Platelet Quality Study
A paired study was completed to verify that in vitro platelet quality (functional assays) of hyperconcentrated leukocyte reduced platelets collected by apheresis on the Trima Accel system, diluted in ISOPLATE SOLUTION, and stored for five days (Test) meet FDA acceptance criteria in comparison to plasma-stored platelets (Control). Table 3 summarizes the in vitro platelet quality data.
| Functional Assay | Isoplate Stored Apheresis Platelets (Test) Average (Standard Deviation) | Plasma Stored Apheresis Platelets (Control) Average (Standard Deviation) |
|---|---|---|
| pH | 7.4 (0.2) | 7.5 (0.1) |
| CD62 Expression; P-Selectin (%) | 22.8 (15.6) | 15.0 (9.8) |
| Morphology Score (Max Score 400) | 289 (49) | 292 (47) |
| Hypotonic Shock Response (%) | 53.3 (12.4) | 55.9 (10.9) |
| Extent of Shape Change (%) | 23.2 (5.0) | 25.0 (6.0) |
The primary outcome for this study was:
pH: 95% or more of test units will have a pH (22 °C) greater than 6.2 with a one-sided confidence interval of 95%
All 66 platelet products collected in this study had pH > 6.2 therefore the primary outcome for pH was met for hyperconcetrated platelets collected on the Trima Accel system and stored in ISOPLATE SOLUTION.
15 REFERENCES
16 HOW SUPPLIED/STORAGE AND HANDLING
ISOPLATE SOLUTION - Platelet Additive Solution [PAS-F] is a clear solution supplied in sterile and nonpyrogenic polyolefin bags. The ISOPLATE SOLUTION bags are packaged 18 bags per case.
| SIZE | CATALOG NUMBER | NDC NUMBER |
|---|---|---|
| 500 mL | 40850 | 14537-408-50 |
STORAGE
Store up to 25 °C [See USP Controlled Room Temperature].
Platelets Pheresis PAS Added Leukocytes Reduced products are stored in a mix of 65% ISOPLATE SOLUTION and 35% plasma. Platelets in the solution can be stored at a concentration range of 0.7 to 2.1 × 106/µL for up to 5 days at 20-24 °C with continuous agitation in the Terumo BCT ELP bag [citrated polyvinyl chloride (PVC)].
PRINCIPAL DISPLAY PANEL - 500 mL Bag Label
Isoplate Solution
Platelet Additive Solution [PAS-F]
Catalog # 40850
Polyolefin Bag
500 mL
NDC 14537-408-50
Sterile. Non-pyrogenic. Do not use unless the solution is clear and
the container is intact. Rx only. Single use container.
Caution: Not for direct intravenous infusion.
Recommended storage: Store up to 25 °C (See USP Controlled Room
Temperature).
Each 100 mL contains:
Sodium Chloride USP 0.53 g
Sodium Gluconate USP 0.5 g
Sodium Acetate Trihydrate USP 0.37 g
Potassium Chloride USP 0.037 g
Magnesium Chloride Hexahydrate USP 0.03 g
Dibasic Sodium Phosphate Dihydrate USP 0.008 g
Monobasic Potassium Phosphate NF 0.00082 g
In Water for Injection USP
Manufactured by Terumo BCT, Inc.
10811 W. Collins Ave., Lakewood CO 80215, USA
777969-551
TERUMOBCT
Lot
Expiry Date
INGREDIENTS AND APPEARANCE
| ISOPLATE
sodium chloride, sodium gluconate, sodium acetate, potassium chloride, magnesium chloride, sodium phosphate, dibasic, and potassium phosphate, monobasic solution |
|||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
| Labeler - Terumo BCT Ltd. (233649834) |